Physician profile
William A Capo
NPI 1356316822
$40,467.87
in general payments reported to CMS, 2019-2025
30 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $11K · 2021: $7,935 · 2022: $4,389 · 2023: $3,684 · 2024: $1,407 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,514 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,513.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $21,592.02 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $10,153.66 | 2019-2025 | |
| Abbott Laboratories | $2,039.41 | 2019-2024 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $812.88 | 2019-2025 | Eliquis, Camzyos |
| Cvrx, INC. | $793.35 | 2021-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $785.66 | 2019-2024 | Jardiance |
| Medtronic, INC. | $599.77 | 2021-2024 | Reveal Linq, Micra |
| Boston Scientific Corporation | $576.14 | 2019-2025 | Farapulse, Watchman Flx, Bodyguardian |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $470.66 | 2019-2025 | Lifevest |
| Amgen INC. | $425.38 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $375.26 | 2019-2025 | |
| Medtronic Vascular, INC. | $241.77 | 2019-2020 | |
| Edwards Lifesciences Corporation | $226.19 | 2022-2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $204.00 | 2021 | |
| Atricure, INC. | $197.32 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $148.52 | 2025 | |
| Impulse Dynamics (USA) INC. | $132.30 | 2023 | Optimizer |
| Amarin Pharma, INC. | $119.50 | 2019-2021 | |
| Biotronik INC. | $116.27 | 2024 | Amvia Edge |
| Biosense Webster, INC. | $102.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.50 | 2021-2025 | |
| Philips North America LLC | $62.71 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $44.69 | 2023 | Inpefa |
| Siemens Medical Solutions USA, INC. | $36.66 | 2024 | Artis Icono Floor |
| Kowa Pharmaceuticals America, INC. | $35.20 | 2019-2021 | |
| Angiodynamics, INC. | $26.98 | 2022 | |
| Scpharmaceuticals INC. | $25.07 | 2025 | |
| Esperion Therapeutics, INC. | $20.18 | 2021 | |
| Irhythm Technologies, INC. | $19.33 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.76 | 2023 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Capo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.